 |
Cellular therapy products such as CAR-T show promising clinical efficacy in fighting cancer. But the accompanying risk of fast-onset cytokine release syndrome (CRS) has driven a standard of care that includes lengthy hospital stays following infusion. Long hospital stays—often 2 weeks—present a high risk for infection along with a high financial and emotional burden for patients and families, and ultimately drive-up costs and reduce the accessibility of these therapies. In this webinar, we’ll discuss recent research at Mount Sinai evaluating the feasibility of dramatically reducing hospital stays for patients undergoing CAR-T therapy through the use of continuous safety monitoring in the Current Health platform.Study leaders will:
|
